617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II

Identifying patients at risk of prolonged neutropenia and enhanced risk of complications during AZA VEN induction for AML

A novel strategy to circumvent venetoclax resistance in relapsed refractory Acute Myeloid Leukemia

Thioguanine and decitabine can overcome hypomethylating agent resistance in patients with advanced myeloid malignancies

Outcomes with ATO ATRA based regimen in apml steroid induced toxicities are a concern in LMICs

Outcomes in patients with newly diagnosed Acute Myeloid Leukemia with KMT2A rearrangement treated with cladribine idarubicin cytarabine CLIA with or without venetoclax

A prospective clinical study of venetoclax plus azacitidine for the maintenance treatment of post remission Acute Myeloid Leukemia

Cladribine based low intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia AML and renal impairment

Venetoclax plus mitoxantrone hydrochloride liposome and Azacitidine As first line treatment for adults with Acute Myeloid Leukemia

Ivosidenib in refractory or relapsed IDH1 mutated Acute Myeloid Leukemia patients in real life settings The ivoobs observational study from the french AML intergroup ALFA filo

A study on the efficacy safety and mechanism of venetoclax combined with CAR T targeting CLL1 in the treatment of Acute Myeloid Leukemia

Genotype guided comparison of ven HMA versus intensive chemotherapy in newly diagnosed intermediate risk AML A multicenter real world study

Venetoclax combined with three day multi frequency decitabine DEC3 VEN VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia a phase III prospective multicenter randomized controlled trial

Early real world experience with revumenib outside of a clinical trial setting A single center retrospective review of efficacy and tolerability

Epigenetic priming improves survival for pediatric Acute Myeloid Leukemia Results from the multicenter randomized AML16 trial

Impact of G CSF in AML patients treated with venetoclax and azacitidine A dataml registry study

Clinical outcome of patients with TP53 AML treated with non intensive vidaza venetoclax chemotherapy Venaura retrospective regional multicenter study

Oral azacitidine maintenance improved survival for t AML or AML MR patients in first remission after CPX 351 and not eligible to HSCT

CYP3A4 inhibitors CYP3A4i and myelosuppression in patients Pts with newly diagnosed mutant isocitrate dehydrogenase 1 mIDH1 Acute Myeloid Leukemia AML in the phase 3 AGILE study

Analysis of hematologic improvement HI by time to response in Relapsed Refractory Acute Myeloid Leukemia AML patients treated with olutasidenib

Elderly Acute Myeloid Leukemia AML with NPM1 or FLT3 ITD mutated Is venetoclax the game changer also in fit patients a real life retrospective analysis by the rete ematologica lombarda

Molecular subtype combined with peripheral blast clearance rate to optimize the treatment of newly diagnosed Acute Myeloid Leukemia Interim analysis of the multicenter Phase II study IA X 2024

Prognostic impact of cognitive and other impairments in older adults with acute myeloid leukemia AML participating in a geriatric assessment guided treatment selection trial

Efficacy and safety of clia plus venetoclax as salvage therapy for relapsed or refractory Acute Myeloid Leukemia